IMGN - ImmunoGen Inc Stock Price, Fair Value and News

31.23USD Market Closed

Market Summary

USD31.23

Market Closed

IMGN Stock Price

View Fullscreen

IMGN RSI Chart

IMGN Valuation

Market Cap

8.3B

Price/Earnings (Trailing)

-113.1

Price/Sales (Trailing)

28.91

EV/EBITDA

-35.08

Price/Free Cashflow

-41.62

IMGN Price/Sales (Trailing)

IMGN Profitability

EBT Margin

-38.01%

Return on Equity

-13.09%

Return on Assets

-8.94%

Free Cashflow Yield

-2.4%

IMGN Fundamentals

IMGN Revenue

Revenue (TTM)

287.6M

Rev. Growth (Yr)

637.72%

Rev. Growth (Qtr)

36.41%

IMGN Earnings

Earnings (TTM)

-73.5M

Earnings Growth (Yr)

139.54%

Earnings Growth (Qtr)

823.82%

Breaking Down IMGN Revenue

Last 7 days

6.7%

Last 30 days

5.3%

Last 90 days

111.6%

Trailing 12 Months

570.2%

How does IMGN drawdown profile look like?

IMGN Financial Health

Current Ratio

5.7

Debt/Equity

Debt/Cashflow

-94.91

IMGN Investor Care

Shares Dilution (1Y)

20.62%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	120.6M	189.6M	287.6M	0
2022	92.2M	89.4M	95.6M	108.8M
2021	134.7M	136.6M	127.7M	69.9M
2020	87.0M	86.5M	91.4M	132.3M
2019	42.2M	48.5M	50.8M	82.3M
2018	106.8M	77.0M	79.5M	53.4M
2017	57.4M	89.0M	89.8M	115.4M
2016	65.2M	60.0M	52.8M	48.6M
2015	78.7M	85.5M	87.2M	56.9M
2014	58.0M	59.9M	55.9M	74.1M
2013	34.7M	35.5M	48.7M	76.1M
2012	19.9M	16.4M	17.9M	12.9M
2011	18.0M	19.3M	18.4M	21.9M
2010	0	13.9M	15.3M	16.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ImmunoGen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 12, 2024	vasconcelles michael	back to issuer	-	-	-1,327	evp r&d & medical affairs
Feb 12, 2024	arbuckle stuart a	back to issuer	-	-	-5,381	-
Feb 12, 2024	coen stacy ann	back to issuer	-	-	-73,274	svp & chief business officer
Feb 12, 2024	wallace richard john	back to issuer	-	-	-10,000	-
Feb 12, 2024	lentini renee	back to issuer	-	-	-14,723	vp & prin acctg officer
Feb 12, 2024	goldberg mark alan	back to issuer	-	-	-60,720	-
Feb 12, 2024	mitchell dean j	back to issuer	-	-	-103,000	-
Feb 12, 2024	thackray helen m.	back to issuer	-	-	-3,074	-
Feb 12, 2024	enyedy mark j	back to issuer	-	-	-584,397	chief executive officer
Feb 12, 2024	char daniel	back to issuer	-	-	-1,000	svp & chief legal officer

Which funds bought or sold IMGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-264,419	-	-%
Apr 10, 2024	SOA Wealth Advisors, LLC.	sold off	-100	-1,987	-	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	1,838	1,838	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-21,000	-	-%
Apr 05, 2024	GAMMA Investing LLC	sold off	-100	-5,629	-	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	sold off	-100	-1,250,340	-	-%
Mar 29, 2024	Kapitalo Investimentos Ltda	new	-	932,107	932,107	0.19%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	8.14	9,149	18,116	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	added	495	48,173,000	52,934,000	0.18%
Mar 14, 2024	Leo Wealth, LLC	new	-	741,724	741,724	0.08%

Are Funds Buying or Selling IMGN?

Are funds buying IMGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMGN

No. of Funds

Unveiling ImmunoGen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	redmile group, llc	5.9%	16,423,922	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	26,916,027	SC 13G/A
Feb 13, 2024	vanguard group inc	9.13%	25,466,950	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	0.35%	971,928	SC 13G/A
Jan 25, 2024	blackrock inc.	8.2%	21,823,243	SC 13G/A
Jan 22, 2024	state street corp	3.02%	8,075,671	SC 13G/A
Feb 14, 2023	redmile group, llc	8.6%	19,896,453	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	22,075,158	SC 13G/A
Feb 10, 2023	flynn james e	2.88%	6,358,314	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of ImmunoGen Inc

View All Filings

Date Filed	Form Type	Document
Feb 22, 2024	15-12G	15-12G
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	S-8 POS	Employee Benefits Plan
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	8-K	Current Report
Feb 12, 2024	S-8 POS	Employee Benefits Plan
Feb 12, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to ImmunoGen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

ImmunoGen Inc News

Latest updates

ImmunoGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	36.4%	113,425,000	83,153,000	49,869,000	41,167,000	15,375,000	14,162,000	38,078,000	27,992,000	9,210,000	16,948,000	15,706,000	85,798,000	18,189,000	15,025,000	13,287,000	44,864,000	13,281,000	15,542,000	8,584,000	13,416,000	10,928,000
Operating Expenses	0.1%	87,469,000	87,342,000	92,262,000	100,726,000	92,804,000	75,215,000	60,930,000	62,546,000	43,444,000	44,317,000	44,622,000	49,279,000	34,916,000	33,387,000	37,097,000	36,370,000	31,243,000	56,601,000	50,230,000	53,839,000	56,460,000
S&GA Expenses	3.8%	37,744,000	36,356,000	40,016,000	42,065,000	33,623,000	23,793,000	16,648,000	13,578,000	10,297,000	9,728,000	10,209,000	9,738,000	10,231,000	9,767,000	8,864,000	9,803,000	9,208,000	8,700,000	10,778,000	9,752,000	8,347,000
R&D Expenses	-5.0%	47,570,000	50,077,000	51,620,000	58,485,000	59,181,000	51,422,000	44,282,000	48,968,000	33,147,000	34,589,000	34,413,000	39,578,000	24,685,000	22,921,000	27,408,000	26,055,000	21,015,000	28,559,000	38,893,000	43,681,000	47,243,000
EBITDA Margin	34.1%	-0.76	-1.16	-1.82	-2.02	-1.44	-1.54	-1.49	-1.96	-0.33	-0.31	-0.31	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	2,539,000	-	-	-	-	-	-	-	-	23,000	24,000	24,000	24,000	23,000	24,000	24,000	24,000	23,000	24,000	25,000	23,000
Income Taxes	-233.0%	-1,166,000	877,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	977.5%	29,582,000	-3,371,000	-	-57,790,000	-77,755,000	-62,021,000	-	-	-	-	-	9,464,000	-	-	-	-	-	-	-	-	-
EBT Margin	67.5%	-0.38	-1.17	-1.84	-2.04	-1.46	-1.56	-1.51	-1.99	-0.35	-0.32	-0.33	-	-	-	-	-	-	-	-	-	-
Net Income	823.8%	30,748,000	-4,248,000	-41,014,000	-59,008,000	-77,755,000	-62,021,000	-24,145,000	-37,172,000	-37,339,000	-30,741,000	-34,051,000	31,388,000	-22,374,000	-24,298,000	-29,088,000	4,814,000	-21,750,000	-43,446,000	-43,751,000	-41,799,000	-46,807,000
Net Income Margin	73.4%	-0.26	-0.96	-1.99	-2.05	-2.10	-1.80	-1.40	-1.99	-0.55	-0.41	-0.37	-	-	-	-	-	-	-	-	-	-
Free Cashflow	102.1%	1,416,000	-66,819,000	-73,928,000	-60,447,000	-64,812,000	-64,198,000	-41,709,000	-46,243,000	-35,167,000	-43,926,000	-45,514,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	15.1%	822	714	288	349	359	422	482	526	297	301	346	355	248	270	299	235	254	288	324	295	340
Current Assets	14.6%	767	669	244	304	330	394	457	500	271	274	320	324	219	241	271	209	226	259	290	279	323
Cash Equivalents	5.9%	606	572	201	275	310	374	438	479	246	240	283	479	188	220	247	176	204	240	270	262	303
Inventory	70.0%	5.00	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00
Net PPE	17.3%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	7.00	9.00	10.00	14.00	13.00	13.00
Liabilities	16.6%	261	223	166	193	181	172	175	200	220	233	252	266	291	294	303	311	340	356	352	284	293
Current Liabilities	43.7%	135	94.00	102	122	104	87.00	84.00	101	112	120	134	122	100	91.00	86.00	77.00	88.00	75.00	61.00	71.00	70.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	1.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	14.4%	562	491	122	156	178	250	306	326	77.00	68.00	94.00	90.00	-	-	-	-	-	-	-	11.00	47.00
Retained Earnings	-0.5%	-1,708	-1,700	-1,735	-1,694	-1,600	-1,557	-1,500	-1,471	-1,400	-1,396	-1,400	-1,331	-1,400	-1,300	-1,300	-1,287	-1,292	-1,270	-1,227	-1,183	-1,141
Additional Paid-In Capital	1.8%	2,268	2,228	1,855	1,848	1,811	1,805	1,800	1,795	1,509	1,463	1,458	1,419	1,319	1,315	1,311	1,210	1,205	1,201	1,198	1,193	1,187
Shares Outstanding	6.9%	266	249	226	226	253	253	253	220	201	200	199	176	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	990	-	-	-	1,314	-	-	-	799	-	-	-	321	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	104.2%	2,770	-66,741	-73,719	-60,199	-64,210	-63,991	-41,402	-45,874	-35,042	-43,879	-44,621	8,535	-30,647	-28,193	-28,315	-32,557	-35,000	-31,013	10,203	-41,285	-39,856
Share Based Compensation	5.9%	7,874	7,433	7,067	10,753	5,482	4,973	4,407	6,433	3,477	3,742	3,823	3,867	3,878	3,454	3,122	3,228	3,626	2,206	5,107	4,525	4,410
Cashflow From Investing	-1635.9%	-1,354	-78.00	-209	-248	-602	-207	-307	-369	-125	-47.00	-893	-102	-771	-23.00	1,405	2,229	-407	-228	-2,127	-1,026	-2,093
Cashflow From Financing	-92.7%	32,132	437,557	39.00	26,074	449	411	620	279,232	41,390	344	34,778	97,206	129	423	97,984	2,062	73.00	670	68.00	1,358	96.00

IMGN Income Statement

2023-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 113,425	$ 15,375	$ 246,447	$ 67,615
Cost and operating expenses:
Cost of sales	2,155		3,690
Research and development	47,570	59,181	149,267	154,885
Selling, general and administrative	37,744	33,623	114,116	74,064
Total cost and operating expenses	87,469	92,804	267,073	228,949
Income (loss) from operations	25,956	(77,429)	(20,626)	(161,334)
Interest income	7,383	1,539	14,775	2,183
Interest expense on term loan	(2,539)		(5,857)
Non-cash interest expense on liability related to the sale of future royalties and term loan	(1,054)	(867)	(2,986)	(3,194)
Other (expense) income, net	(164)	(998)	(109)	(1,576)
Net loss before income taxes	29,582	(77,755)	(14,803)	(163,921)
Income tax benefit	(1,166)		(289)
Net loss	$ 30,748	$ (77,755)	$ (14,514)	$ (163,921)
Net income (loss) per common share - basic (Note B)	$ 0.10	$ (0.31)	$ (0.05)	$ (0.65)
Net income (loss) per common share - diluted (Note B)	$ 0.10	$ (0.31)	$ (0.05)	$ (0.65)
Basic weighted average common shares outstanding (in shares)	273,341	253,511	265,265	253,371
Diluted weighted average common shares outstanding (in shares)	287,590	253,511	265,265	253,371
License and milestone fees
Revenues:
Total revenues	$ 51	$ 7,382	$ 15,122	$ 45,247
Non-cash royalty revenue related to the sale of future royalties
Revenues:
Total revenues	7,355	$ 7,993	17,936	21,537
Research and development support
Revenues:
Total revenues	855		1,310	$ 831
Product revenue, net
Revenues:
Total revenues	$ 105,164		$ 212,079

IMGN Balance Sheet

2023-09-30

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 605,535,000	$ 275,138,000
Accounts receivable	130,694,000	12,596,000
Unbilled receivable	3,026,000	1,531,000
Non-cash royalty receivable	3,438,000	3,851,000
Inventory	5,495,000
Prepaid and other current assets	18,712,000	11,005,000
Total current assets	766,900,000	304,121,000
Property and equipment, net of accumulated depreciation	4,431,000	4,377,000
Operating lease right-of-use assets	8,338,000	10,231,000
Long-term inventory	28,273,000	16,196,000
Other assets	14,159,000	14,011,000
Total assets	822,101,000	348,936,000
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable	24,853,000	45,353,000
Accrued compensation	15,155,000	11,111,000
Other accrued liabilities	43,571,000	38,783,000
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $128 and $162, respectively	9,437,000	8,659,000
Current portion of operating lease liability	4,458,000	4,096,000
Current portion of deferred revenue	37,186,000	13,856,000
Total current liabilities	134,660,000	121,858,000
Senior secured term loan, net	72,113,000
Deferred revenue, net of current portion	26,718,000	36,355,000
Operating lease liability, net of current portion	7,759,000	11,148,000
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $111 and $205, respectively	16,455,000	23,449,000
Other long-term liabilities	2,800,000	300,000
Total liabilities	260,505,000	193,110,000
Commitments and contingencies (Note K)
Shareholders' equity:
Preferred stock, $.01 par value; authorized 5,000 shares; 22 and 0 shares issued and outstanding as of each of September 30, 2023 and December 31, 2022, respectively
Common stock, $.01 par value; authorized 600,000 shares; 265,842 and 220,046 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	2,435,000	2,260,000
Additional paid-in capital	2,267,747,000	1,847,638,000
Accumulated deficit	(1,708,586,000)	(1,694,072,000)
Total shareholders' equity	561,596,000	155,826,000
Total liabilities and shareholders' equity	$ 822,101,000	$ 348,936,000

About ImmunoGen Inc

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Mark Joseph Enyedy
WEBSITE	immunogen.com
INDUSTRY	Biotechnology
EMPLOYEES	277

ImmunoGen Inc Frequently Asked Questions

What is the ticker symbol for ImmunoGen Inc? What does IMGN stand for in stocks?

IMGN is the stock ticker symbol of ImmunoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunoGen Inc (IMGN)?

As of Tue Feb 13 2024, market cap of ImmunoGen Inc is 8.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMGN stock?

You can check IMGN's fair value in chart for subscribers.

What is the fair value of IMGN stock?

You can check IMGN's fair value in chart for subscribers. The fair value of ImmunoGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmunoGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmunoGen Inc a good stock to buy?

The fair value guage provides a quick view whether IMGN is over valued or under valued. Whether ImmunoGen Inc is cheap or expensive depends on the assumptions which impact ImmunoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMGN.

What is ImmunoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 13 2024, IMGN's PE ratio (Price to Earnings) is -113.1 and Price to Sales (PS) ratio is 28.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ImmunoGen Inc's stock?

In the past 10 years, ImmunoGen Inc has provided 0.077 (multiply by 100 for percentage) rate of return.